<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403622</url>
  </required_header>
  <id_info>
    <org_study_id>1410006671</org_study_id>
    <nct_id>NCT02403622</nct_id>
  </id_info>
  <brief_title>Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>STOOL</acronym>
  <official_title>Safety of Fecal Microbiota Transplantation: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microbiome Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edward Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Microbiome Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective of this study is to address the knowledge gap regarding the
      short-term and long-term safety of fecal microbiota transplants (FMT). The design will be a
      prospective, open-label, multi-center longitudinal cohort study to assess the short- and
      long-term safety of FMT as well as the clinical resolution of diarrhea among 150 patients
      with 3 or more episodes of clostridium difficile infection (CDI defined as 3 unformed stools
      over 24 hours for 2 consecutive days and either a positive stool test for CDI or
      pseudomembranes on colonoscopy/sigmoidoscopy). Subjects will be adult outpatients referred
      to one of the study centers after at least three recurrent episodes of CDI and previous
      treatment with at least one 10-day course of oral vancomycin or fidaxomicin. After FMT by
      colonoscopy/sigmoidoscopy or enema, patients will be followed prospectively and monitored
      for clinical resolution and adverse events at: 3 days (telephone), 3 weeks (clinical
      assessment), 8 weeks (telephone), 6 months (telephone), and 12 months (telephone) after FMT.
      Subjects who recur will be offered a second FMT by colonoscopy with a different donor.
      Microbiome analysis will be conducted from stool samples at baseline and each of the 5
      follow-up intervals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term safety of FMT as measured by absence or presence of adverse events</measure>
    <time_frame>&lt; 6 weeks post FMT</time_frame>
    <description>Determine the short-term safety of FMT for the prevention of further CDI recurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term safety of FMT as measured by absence or presence of adverse events</measure>
    <time_frame>&gt; 6 weeks to 1 year post FMT</time_frame>
    <description>Determine the long-term safety of FMT for the prevention of further CDI recurrence</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Clostridium Difficile</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fecal Microbiota Preparations</intervention_name>
    <description>Frozen processed human fecal material for treating recurrent clostridium difficile infections.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult outpatients with third or further documented CDI episode.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (at least 18 years of age)

          -  Outpatient

          -  Third or further documented CDI episode and

          -  Unable to maintain CDI cure after standard therapy with oral vancomycin or
             fidaxomicin

               -  Previous treatment with at least one course of tapered/pulse vancomycin or

               -  Inability to taper or stop vancomycin or fidaxomicin without developing diarrhea
                  requiring antibiotic therapy.

          -  Improvement of CDI symptoms on vancomycin or fidaxomicin

        Exclusion Criteria:

          -  Unable to comply with study follow-up procedures or travel to clinical site for
             follow-up visits at discretion of MD

          -  Unable to provide informed consent at discretion of MD

          -  Participating in another clinical trial

          -  Pregnant or nursing currently or planned pregnancy in next 1 year

          -  Evidence of toxic megacolon or gastrointestinal perforation

          -  Peripheral white blood cell count &gt;30 x 109/L and/or temperature &gt;38 degrees Celsius

          -  Admission to an intensive care unit within prior 7 days for any reason

          -  Previously undergone FMT

          -  Severely immunocompromised patients

             o Documented history (self- or physician identified) HIV infection with any cluster
             of differentiation 4 (CD4) count

               -  AIDS-defining diagnoses

               -  Inherited/primary immune disorder

               -  Immunosuppressant medications

          -  Neutropenia with absolute neutrophil count (ANC) &lt;0.5 x 109/L

          -  Active gastroenteritis due to infectious cause other than CDI

          -  Short gut syndrome

          -  Colostomy

          -  Ascites

          -  End-stage liver disease

          -  Untreated, in-situ colorectal cancer

          -  Irritable bowel syndrome

          -  Inflammatory bowel disease including Crohn's disease and ulcerative colitis

          -  Microscopic colitis including collagenous colitis and lymphocytic colitis

          -  Severe food allergy (anaphylaxis) that cannot be confirmed as having been excluded
             from a donor's diet within the five days prior to donation

          -  Anorectal disorder/severe rectal sphincter tone abnormality or inability to retain
             enema material

          -  Unable or unwilling to tolerate colonoscopy/sigmoidoscopy, colonoscopy prep, or enema
             for any reason at discretion of MD

          -  Severe underlying disease that the patient is not expected to survive for the
             subsequent 12 months at the discretion of the MD.

          -  Any conditions for which, in opinion of MD, the treatment may pose a health risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zain Kassam, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>OpenBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zain Kassam, MD, MPH</last_name>
    <phone>617-575-2201</phone>
    <phone_ext>700</phone_ext>
    <email>zain@openbiome.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robyn Day, AB</last_name>
    <phone>617-575-2201</phone>
    <phone_ext>725</phone_ext>
    <email>robyn@openbiome.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Edward Hospital</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Kastin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Darren Kastin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Fischer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monika Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Dickstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aaron Dickstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Aroniadis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Aroniadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ari Grinspan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ari Grinspan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Kelly, MD</last_name>
    </contact>
    <investigator>
      <last_name>Colleen Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Flynn, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ann Flynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hays, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Hays, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 1, 2016</lastchanged_date>
  <firstreceived_date>March 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
